JP2015514423A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015514423A5 JP2015514423A5 JP2015507095A JP2015507095A JP2015514423A5 JP 2015514423 A5 JP2015514423 A5 JP 2015514423A5 JP 2015507095 A JP2015507095 A JP 2015507095A JP 2015507095 A JP2015507095 A JP 2015507095A JP 2015514423 A5 JP2015514423 A5 JP 2015514423A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- polypeptide
- amino acid
- acid sequence
- bispecific antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920001184 polypeptide Polymers 0.000 claims 14
- 102000004965 antibodies Human genes 0.000 claims 12
- 108090001123 antibodies Proteins 0.000 claims 12
- 125000003275 alpha amino acid group Chemical group 0.000 claims 11
- 210000004962 mammalian cells Anatomy 0.000 claims 8
- 229920003013 deoxyribonucleic acid Polymers 0.000 claims 4
- 229920000023 polynucleotide Polymers 0.000 claims 4
- 239000002157 polynucleotide Substances 0.000 claims 4
- 206010002556 Ankylosing spondylitis Diseases 0.000 claims 2
- 208000005777 Lupus Nephritis Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 206010037162 Psoriatic arthropathy Diseases 0.000 claims 2
- 206010039073 Rheumatoid arthritis Diseases 0.000 claims 2
- 206010040767 Sjogren's syndrome Diseases 0.000 claims 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims 2
- 201000009251 multiple myeloma Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 201000004681 psoriasis Diseases 0.000 claims 2
- 201000001263 psoriatic arthritis Diseases 0.000 claims 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 2
- 235000001014 amino acid Nutrition 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 210000004027 cells Anatomy 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Claims (12)
- ２つの第１のポリペプチドおよび２つの第２のポリペプチドを含む二重特異性抗体であって、前記第１のポリペプチドのアミノ酸配列は配列番号１であり、前記第２のポリペプチドのアミノ酸配列は配列番号２である、二重特異性抗体。
- 配列番号１のシステイン残基５０７と配列番号１のシステイン残基７０７との間に鎖内ジスルフィド結合が形成されている、請求項１に記載の二重特異性抗体。
- 配列番号１のアミノ酸配列を有するポリペプチドをコードするポリヌクレオチド配列および配列番号２のアミノ酸配列を有するポリペプチドをコードするポリヌクレオチド配列を含むＤＮＡ分子。
- 配列番号１のアミノ酸配列を有するポリペプチドをコードするポリヌクレオチド配列を含むＤＮＡ分子、および配列番号２のアミノ酸配列を有するポリペプチドをコードするポリヌクレオチド配列を含むＤＮＡ分子を含む哺乳動物細胞であって、前記細胞は、配列番号１のアミノ酸配列を有する第１のポリペプチドおよび配列番号２のアミノ酸配列を有する第２のポリペプチドを含む二重特異性抗体を発現できる、哺乳動物細胞。
- 請求項３に記載のＤＮＡ分子で形質転換された哺乳動物細胞であって、前記細胞は、アミノ酸配列が配列番号１である第１のポリペプチドおよびアミノ酸配列が配列番号２である第２のポリペプチドを含む二重特異性抗体を発現できる、哺乳動物細胞。
- 前記哺乳動物細胞はＣＨＯである、請求項４または５に記載の哺乳動物細胞。
- アミノ酸配列が配列番号１である第１のポリペプチドおよびアミノ酸配列が配列番号２である第２のポリペプチドを含む、二重特異性抗体を産生する方法であって、前記二重特異性抗体が発現されるような条件下で請求項４に記載の哺乳動物細胞または請求項５に記載の哺乳動物細胞を培養することと、発現した二重特異性抗体を回収することとを含む、方法。
- 請求項７に記載の方法によって産生される二重特異性抗体。
- 治療に使用するための請求項１または８に記載の二重特異性抗体。
- 全身性エリテマトーデス、ループス腎炎、関節リウマチ、乾癬、強直性脊椎炎、乾癬性関節炎、原発性シェーグレン症候群、または多発性骨髄腫の治療に使用するための請求項１または８に記載の二重特異性抗体。
- 請求項１または８に記載の二重特異性抗体と、１つ以上の薬学的に許容可能な担体、希釈剤または賦形剤とを含む医薬組成物。
- 全身性エリテマトーデス、ループス腎炎、関節リウマチ、乾癬、強直性脊椎炎、乾癬性関節炎、原発性シェーグレン症候群、または多発性骨髄腫の治療に使用するための、請求項１１に記載の医薬組成物。
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261636302P | 2012-04-20 | 2012-04-20 | |
| US61/636,302 | 2012-04-20 | ||
| US201361768747P | 2013-02-25 | 2013-02-25 | |
| US61/768,747 | 2013-02-25 | ||
| PCT/US2013/036677 WO2013158577A1 (en) | 2012-04-20 | 2013-04-16 | Anti-baff-anti-il-17 bispecific antibodies |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015514423A JP2015514423A (ja) | 2015-05-21 |
| JP2015514423A5 true JP2015514423A5 (ja) | 2016-06-02 |
| JP6216772B2 JP6216772B2 (ja) | 2017-10-18 |
Family
ID=48539373
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015507095A Active JP6216772B2 (ja) | 2012-04-20 | 2013-04-16 | 抗ｂａｆｆ−抗ｉｌ−１７二重特異性抗体 |
Country Status (40)
| Country | Link |
|---|---|
| US (2) | US9359448B2 (ja) |
| EP (2) | EP2838920B1 (ja) |
| JP (1) | JP6216772B2 (ja) |
| KR (1) | KR101673735B1 (ja) |
| CN (1) | CN104220455B (ja) |
| AP (1) | AP2014008002A0 (ja) |
| AR (1) | AR090626A1 (ja) |
| AU (1) | AU2013249546B2 (ja) |
| BR (1) | BR112014025649A2 (ja) |
| CA (1) | CA2869148C (ja) |
| CL (1) | CL2014002616A1 (ja) |
| CO (1) | CO7160039A2 (ja) |
| CR (1) | CR20140466A (ja) |
| CY (1) | CY1118824T1 (ja) |
| DK (1) | DK2838920T3 (ja) |
| DO (1) | DOP2014000234A (ja) |
| EA (1) | EA029185B1 (ja) |
| EC (1) | ECSP14023405A (ja) |
| ES (2) | ES2621917T3 (ja) |
| GT (1) | GT201400217A (ja) |
| HK (1) | HK1201862A1 (ja) |
| HR (1) | HRP20170468T1 (ja) |
| HU (1) | HUE032153T2 (ja) |
| IL (1) | IL234965B (ja) |
| IN (1) | IN2014MN01876A (ja) |
| LT (1) | LT2838920T (ja) |
| ME (1) | ME02596B (ja) |
| MX (1) | MX367460B (ja) |
| MY (1) | MY173282A (ja) |
| NZ (1) | NZ630865A (ja) |
| PE (1) | PE20142147A1 (ja) |
| PH (1) | PH12014502333A1 (ja) |
| PL (1) | PL2838920T3 (ja) |
| PT (1) | PT2838920T (ja) |
| RS (1) | RS55729B1 (ja) |
| SG (1) | SG11201406726PA (ja) |
| SI (1) | SI2838920T1 (ja) |
| TW (1) | TWI585103B (ja) |
| WO (1) | WO2013158577A1 (ja) |
| ZA (1) | ZA201407272B (ja) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2012149227A (ru) | 2010-05-20 | 2014-06-27 | Аблинкс Нв | Биологические материалы, относящиеся к her3 |
| UA117218C2 (uk) | 2011-05-05 | 2018-07-10 | Мерк Патент Гмбх | Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f |
| AR090626A1 (es) * | 2012-04-20 | 2014-11-26 | Lilly Co Eli | Anticuerpos anti-baff-anti-il-17 biespecificos |
| TW201444867A (zh) * | 2013-03-08 | 2014-12-01 | Lilly Co Eli | 抗ｔｎｆ－抗ｉｌ－１７雙特異性抗體 |
| US9458246B2 (en) | 2013-03-13 | 2016-10-04 | Amgen Inc. | Proteins specific for BAFF and B7RP1 |
| JOP20140087B1 (ar) | 2013-03-13 | 2021-08-17 | Amgen Inc | بروتينات مخصصة ل baff و b7rp1 وإستخداماتها |
| CA2929846C (en) * | 2013-11-19 | 2020-09-15 | Regeneron Pharmaceuticals, Inc. | Non-human animals having a humanized b-cell activating factor gene |
| WO2016039801A1 (en) | 2014-01-31 | 2016-03-17 | Boehringer Ingelheim International Gmbh | Novel anti-baff antibodies |
| AR102417A1 (es) | 2014-11-05 | 2017-03-01 | Lilly Co Eli | Anticuerpos biespecíficos anti-tnf- / anti-il-23 |
| TW202144411A (zh) * | 2015-07-23 | 2021-12-01 | 德商包林格因蓋爾漢國際股份有限公司 | 靶向il-23a與b細胞活化因子(baff)之化合物及其用途 |
| CN105061596B (zh) * | 2015-08-05 | 2019-01-29 | 江苏诺迈博生物医药科技有限公司 | 人b淋巴细胞刺激因子的单克隆抗体及其应用 |
| US20200385478A1 (en) * | 2018-01-05 | 2020-12-10 | Biograph 55, Inc. | Compositions and methods for cancer immunotherapy |
| CN117529506A (zh) * | 2021-06-11 | 2024-02-06 | 海南先声药业有限公司 | 抗人il-17抗体和taci的双功能融合蛋白分子 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995009917A1 (en) | 1993-10-07 | 1995-04-13 | The Regents Of The University Of California | Genetically engineered bispecific tetravalent antibodies |
| AR035119A1 (es) * | 2001-08-16 | 2004-04-14 | Lilly Co Eli | Anticuerpos humanos antagonistas anti-htnfsf13b |
| RU2515108C2 (ru) * | 2005-08-19 | 2014-05-10 | Эббви Инк | Иммуноглобулин с двойными вариабельными доменами и его применения |
| KR101158959B1 (ko) | 2005-12-13 | 2012-07-09 | 일라이 릴리 앤드 캄파니 | 항-ｉｌ-17 항체 |
| US20110293629A1 (en) * | 2010-05-14 | 2011-12-01 | Bastid Jeremy | Methods of Treating and/or Preventing Cell Proliferation Disorders with IL-17 Antagonists |
| AR090626A1 (es) * | 2012-04-20 | 2014-11-26 | Lilly Co Eli | Anticuerpos anti-baff-anti-il-17 biespecificos |
-
2013
- 2013-04-08 AR ARP130101134A patent/AR090626A1/es active IP Right Grant
- 2013-04-12 TW TW102113167A patent/TWI585103B/zh not_active IP Right Cessation
- 2013-04-16 DK DK13726321.6T patent/DK2838920T3/en active
- 2013-04-16 PL PL13726321T patent/PL2838920T3/pl unknown
- 2013-04-16 RS RS20170160A patent/RS55729B1/sr unknown
- 2013-04-16 EP EP13726321.6A patent/EP2838920B1/en active Active
- 2013-04-16 JP JP2015507095A patent/JP6216772B2/ja active Active
- 2013-04-16 BR BR112014025649A patent/BR112014025649A2/pt not_active Application Discontinuation
- 2013-04-16 EA EA201491622A patent/EA029185B1/ru not_active IP Right Cessation
- 2013-04-16 LT LTEP13726321.6T patent/LT2838920T/lt unknown
- 2013-04-16 SG SG11201406726PA patent/SG11201406726PA/en unknown
- 2013-04-16 HU HUE13726321A patent/HUE032153T2/en unknown
- 2013-04-16 NZ NZ630865A patent/NZ630865A/en not_active IP Right Cessation
- 2013-04-16 ES ES13726321.6T patent/ES2621917T3/es active Active
- 2013-04-16 IN IN1876MUN2014 patent/IN2014MN01876A/en unknown
- 2013-04-16 AP AP2014008002A patent/AP2014008002A0/xx unknown
- 2013-04-16 US US13/863,544 patent/US9359448B2/en active Active
- 2013-04-16 KR KR1020147028867A patent/KR101673735B1/ko active IP Right Grant
- 2013-04-16 ES ES17153380T patent/ES2789474T3/es active Active
- 2013-04-16 PT PT137263216T patent/PT2838920T/pt unknown
- 2013-04-16 CA CA2869148A patent/CA2869148C/en active Active
- 2013-04-16 EP EP17153380.5A patent/EP3192809B1/en active Active
- 2013-04-16 ME MEP-2017-41A patent/ME02596B/me unknown
- 2013-04-16 PE PE2014001619A patent/PE20142147A1/es active IP Right Grant
- 2013-04-16 CN CN201380020761.7A patent/CN104220455B/zh active Active
- 2013-04-16 MY MYPI2014703075A patent/MY173282A/en unknown
- 2013-04-16 AU AU2013249546A patent/AU2013249546B2/en not_active Ceased
- 2013-04-16 WO PCT/US2013/036677 patent/WO2013158577A1/en active Application Filing
- 2013-04-16 MX MX2014012692A patent/MX367460B/es active IP Right Grant
- 2013-04-16 SI SI201330522A patent/SI2838920T1/sl unknown
-
2014
- 2014-09-30 CL CL2014002616A patent/CL2014002616A1/es unknown
- 2014-10-02 IL IL234965A patent/IL234965B/en active IP Right Grant
- 2014-10-06 CR CR20140466A patent/CR20140466A/es unknown
- 2014-10-07 ZA ZA2014/07272A patent/ZA201407272B/en unknown
- 2014-10-15 GT GT201400217A patent/GT201400217A/es unknown
- 2014-10-16 DO DO2014000234A patent/DOP2014000234A/es unknown
- 2014-10-17 EC ECIEPI201423405A patent/ECSP14023405A/es unknown
- 2014-10-17 PH PH12014502333A patent/PH12014502333A1/en unknown
- 2014-10-20 CO CO14231938A patent/CO7160039A2/es unknown
-
2015
- 2015-03-12 HK HK15102524.4A patent/HK1201862A1/xx not_active IP Right Cessation
-
2016
- 2016-05-18 US US15/157,782 patent/US9708402B2/en active Active
-
2017
- 2017-03-21 HR HRP20170468TT patent/HRP20170468T1/hr unknown
- 2017-03-27 CY CY20171100380T patent/CY1118824T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015514423A5 (ja) | ||
| HRP20170468T1 (hr) | Bispecifična protutijela protiv baff i protiv il-17 | |
| HRP20201633T1 (hr) | Protutijela koja se vežu na il-23 | |
| JP2016526909A5 (ja) | ||
| HRP20192059T1 (hr) | Protutijela protiv tau i njihova upotreba | |
| HRP20191409T1 (hr) | Postupci i sredstva za proizvodnju heterodimernih ig-sličnih molekula | |
| JP2016185981A5 (ja) | ||
| JP2013523179A5 (ja) | ||
| JP2005120106A5 (ja) | ||
| HRP20180155T1 (hr) | Novo protutijelo protiv ljudskog ngf | |
| JP2015146822A5 (ja) | ||
| EA201190326A1 (ru) | Полипептиды гормона роста и способы их получения и применения | |
| JP2017529067A5 (ja) | ||
| JP2016104045A5 (ja) | ||
| RU2014148136A (ru) | Композиции т-клеток с недостаточностью рецепторов т-клеток | |
| EA201691304A1 (ru) | АНТАГОНИСТЫ НЕОНАТАЛЬНЫХ Fc-РЕЦЕПТОРОВ (FcRn) И СПОСОБЫ ИХ ПРИМЕНЕНИЯ | |
| JP2019523221A5 (ja) | ||
| RU2018108836A (ru) | ВАРИАНТЫ Fc И СПОСОБЫ ИХ ПОЛУЧЕНИЯ | |
| JP2016026215A5 (ja) | ||
| MX2019008417A (es) | Cambio de temperatura para una expresion con mayor rendimiento de polipeptidos en levaduras y otras celulas transformadas. | |
| BR112015018203A2 (pt) | Anti-corpos biespecíficos anti-tnf-anti-il-17 | |
| IN2014DN03419A (ja) | ||
| JP2017525343A5 (ja) | ||
| SI2970447T1 (en) | PROTITELES AGAINST PAN-ELR + CXC KEMOCIN | |
| JP2014210797A5 (ja) |